Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2004-10-27
pubmed:abstractText
Erythropoietic protoporphyria (EPP) is an inherited defect of the ferrochelatase (FECH) gene characterized by the accumulation of toxic protoporphyrin in the liver and bone marrow resulting in severe skin photosensitivity. We previously described successful gene therapy of an animal model of the disease with erythroid-specific lentiviral vectors in the absence of preselection of corrected cells. However, the high-level of gene transfer obtained in mice is not translatable to large animal models and humans if there is no selective advantage for genetically modified hematopoietic stem cells (HSCs) in vivo. We used bicistronic SIN-lentiviral vectors coexpressing EGFP or FECH and the G156A-mutated O6-methylguanine-DNA-methyltransferase (MGMT) gene, which allowed efficient in vivo selection of transduced HSCs after O6-benzylguanine and BCNU treatment. We demonstrate for the first time that the correction and in vivo expansion of deficient transduced HSC population can be obtained by this dual gene therapy, resulting in a progressive increase of normal RBCs in EPP mice and a complete correction of skin photosensitivity. Finally, we developed a novel bipromoter SIN-lentiviral vector with a constitutive expression of MGMT gene to allow the selection of HSCs and with an erythroid-specific expression of the FECH therapeutic gene.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0969-7128
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1638-47
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15284838-Animals, pubmed-meshheading:15284838-Antineoplastic Agents, pubmed-meshheading:15284838-Carmustine, pubmed-meshheading:15284838-Female, pubmed-meshheading:15284838-Ferrochelatase, pubmed-meshheading:15284838-Gene Therapy, pubmed-meshheading:15284838-Genetic Engineering, pubmed-meshheading:15284838-Genetic Vectors, pubmed-meshheading:15284838-Guanine, pubmed-meshheading:15284838-Lentivirus, pubmed-meshheading:15284838-Male, pubmed-meshheading:15284838-Mice, pubmed-meshheading:15284838-Mice, Inbred BALB C, pubmed-meshheading:15284838-Models, Animal, pubmed-meshheading:15284838-O(6)-Methylguanine-DNA Methyltransferase, pubmed-meshheading:15284838-Protoporphyria, Erythropoietic, pubmed-meshheading:15284838-Stem Cell Transplantation, pubmed-meshheading:15284838-Stem Cells, pubmed-meshheading:15284838-Transduction, Genetic
pubmed:year
2004
pubmed:articleTitle
Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.
pubmed:affiliation
INSERM E0217, Federative Research Institute 66, Université Victor Segalen Bordeaux 2, Bordeaux France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't